[go: up one dir, main page]

SI2265607T1 - Spojine pirimidin-2-amina in njihova uporaba kot inhibitorji JAK kinaz - Google Patents

Spojine pirimidin-2-amina in njihova uporaba kot inhibitorji JAK kinaz

Info

Publication number
SI2265607T1
SI2265607T1 SI200931620A SI200931620A SI2265607T1 SI 2265607 T1 SI2265607 T1 SI 2265607T1 SI 200931620 A SI200931620 A SI 200931620A SI 200931620 A SI200931620 A SI 200931620A SI 2265607 T1 SI2265607 T1 SI 2265607T1
Authority
SI
Slovenia
Prior art keywords
pyrimidine
inhibitors
amine compounds
jak kinases
jak
Prior art date
Application number
SI200931620A
Other languages
English (en)
Inventor
Somasekhar Bhamidipati
Jeffrey Clough
Ankush Argade
Rajinder Singh
Vadim Markovtsov
Pingyu Ding
Jiaxin Yu
Andy Atuegbu
Hui Hong
Ihab Darwish
Sambiah Thota
Original Assignee
Rigel Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rigel Pharmaceuticals, Inc. filed Critical Rigel Pharmaceuticals, Inc.
Publication of SI2265607T1 publication Critical patent/SI2265607T1/sl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D451/00Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D451/00Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
SI200931620A 2008-02-15 2009-02-13 Spojine pirimidin-2-amina in njihova uporaba kot inhibitorji JAK kinaz SI2265607T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US2926508P 2008-02-15 2008-02-15
US3867208P 2008-03-21 2008-03-21
US11204608P 2008-11-06 2008-11-06
PCT/US2009/034159 WO2009103032A1 (en) 2008-02-15 2009-02-13 Pyrimidine-2-amine compounds and their use as inhibitors of jak kinases

Publications (1)

Publication Number Publication Date
SI2265607T1 true SI2265607T1 (sl) 2017-06-30

Family

ID=40591956

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200931620A SI2265607T1 (sl) 2008-02-15 2009-02-13 Spojine pirimidin-2-amina in njihova uporaba kot inhibitorji JAK kinaz

Country Status (20)

Country Link
US (3) US8309566B2 (sl)
EP (1) EP2265607B1 (sl)
JP (2) JP5711537B2 (sl)
KR (1) KR101700454B1 (sl)
CN (1) CN102007124B (sl)
AU (1) AU2009214440B2 (sl)
CA (1) CA2715658C (sl)
CY (1) CY1118969T1 (sl)
DK (1) DK2265607T3 (sl)
ES (1) ES2617622T3 (sl)
HR (1) HRP20170317T1 (sl)
HU (1) HUE030912T2 (sl)
IL (1) IL207609A (sl)
LT (1) LT2265607T (sl)
MX (1) MX2010008926A (sl)
NZ (1) NZ587589A (sl)
PL (1) PL2265607T3 (sl)
PT (1) PT2265607T (sl)
SI (1) SI2265607T1 (sl)
WO (1) WO2009103032A1 (sl)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101622252B (zh) 2006-12-29 2015-04-22 里格尔制药公司 用作axl抑制剂的取代三唑
CA2710043C (en) 2006-12-29 2016-02-09 Rigel Pharmaceuticals, Inc. Bicyclic aryl and bicyclic heteroaryl substituted triazoles useful as axl inhibitors
ES2607065T3 (es) * 2006-12-29 2017-03-29 Rigel Pharmaceuticals, Inc. Triazoles N3-heteroaril sustituidos y triazoles N5-heteroaril sustituidos útiles como inhibidores de axl
ME01832B (me) 2006-12-29 2014-12-20 Rigel Pharmaceuticals Inc Policiklični heteroaril supstituisani triazoli koji su korisni kao axl inhibitori
PL2114955T3 (pl) 2006-12-29 2013-06-28 Rigel Pharmaceuticals Inc Triazole podstawione mostkowanym bicyklicznym arylem oraz mostkowanym bicyklicznym heteroarylem użyteczne jako inhibitory Axl
ES2535166T3 (es) * 2007-09-04 2015-05-06 The Scripps Research Institute Pirimidinil-aminas sustituidas como inhibidores de proteína-quinasas
JP5635909B2 (ja) * 2007-10-26 2014-12-03 ライジェル ファーマシューティカルズ, インコーポレイテッド Axl阻害剤として有用な多環アリール置換トリアゾール及び多環ヘテロアリール置換トリアゾール
HRP20170317T1 (hr) * 2008-02-15 2017-04-21 Rigel Pharmaceuticals, Inc. Spojevi pirimidin-2-amina i njihova uporaba kao inhibitora jak kinaza
CA2730251C (en) 2008-07-09 2016-08-09 Rigel Pharmaceuticals, Inc. Bridged bicyclic heteroaryl substituted triazoles useful as axl inhibitors
CA2730231C (en) 2008-07-09 2016-10-18 Rigel Pharmaceuticals, Inc. Polycyclic heteroaryl substituted triazoles useful as axl inhibitors
BRPI1007046B1 (pt) 2009-01-16 2019-07-16 Rigel Pharmaceuticals, Inc. Inibidores axl para uso em terapia de combinação para evitar, tratar ou controlar o câncer metastático.
WO2011075560A1 (en) 2009-12-17 2011-06-23 Merck Sharp & Dohme Corp. Aminopyrimidines as syk inhibitors
MA33926B1 (fr) 2009-12-17 2013-01-02 Merck Sharp & Dohme Aminopyrimidines en tant qu'inhibiteurs de la syk
MX2012014158A (es) 2010-06-04 2013-02-07 Hoffmann La Roche Derivados de aminopirimidina como moduladores de proteina cinasa rica repeticiones leucina 2 (lrrk2).
EP2593434A1 (en) 2010-07-16 2013-05-22 Purdue Pharma LP Pyridine compounds as sodium channel blockers
ES2653967T3 (es) 2010-11-10 2018-02-09 Genentech, Inc. Derivados de pirazol aminopirimidina como moduladores de LRRK2
EP2706852B1 (en) 2011-05-10 2018-08-22 Merck Sharp & Dohme Corp. Bipyridylaminopyridines as syk inhibitors
EP2706853B1 (en) 2011-05-10 2017-06-14 Merck Sharp & Dohme Corp. Aminopyrimidines as syk inhibitors
JP2014513687A (ja) 2011-05-10 2014-06-05 メルク・シャープ・アンド・ドーム・コーポレーション Syk阻害薬としてのピリジルアミノピリジン
AU2013203824A1 (en) 2012-03-16 2013-10-03 Purdue Pharma L.P. Substituted pyridines and pryimidines as sodium channel blockers
WO2013173506A2 (en) 2012-05-16 2013-11-21 Rigel Pharmaceuticals, Inc. Method of treating muscular degradation
US8809359B2 (en) * 2012-06-29 2014-08-19 Ym Biosciences Australia Pty Ltd Phenyl amino pyrimidine bicyclic compounds and uses thereof
CN103709172B (zh) * 2012-09-28 2018-02-13 江苏先声药业有限公司 取代呋喃并哌啶衍生物及其应用
US9714252B2 (en) 2012-12-20 2017-07-25 Purdue Pharma L.P. Cyclic sulfonamides as sodium channel blockers
GB201303109D0 (en) 2013-02-21 2013-04-10 Domainex Ltd Novel pyrimidine compounds
KR101665301B1 (ko) 2013-08-07 2016-10-11 카딜라 핼쓰캐어 리미티드 야누스 키나제의 억제제로서 n-시아노메틸아미드
CN104414427A (zh) * 2013-08-26 2015-03-18 皇家飞利浦有限公司 用于准备食物的具有带滑动机构的抽屉的装置
CN104860941B (zh) * 2014-02-25 2017-03-22 上海海雁医药科技有限公司 2,4‑二取代苯‑1,5‑二胺衍生物及其应用以及由其制备的药物组合物和药用组合物
US10730866B2 (en) 2014-04-07 2020-08-04 Purdue Pharma L.P. Indole derivatives and use thereof
AU2016228660B2 (en) * 2015-03-11 2020-05-07 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Substituted 2-hydrogen-pyrazole derivative serving as anticancer drug
WO2017007658A1 (en) * 2015-07-07 2017-01-12 Rigel Pharmaceuticals, Inc. A combination for immune mediated cancer treatment
CN106810536A (zh) * 2015-11-30 2017-06-09 甘李药业股份有限公司 一种蛋白激酶抑制剂及其制备方法和医药用途
GB201702947D0 (en) 2017-02-23 2017-04-12 Domainex Ltd Novel compounds
US12171764B2 (en) 2018-06-20 2024-12-24 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with a JAK or other kinase inhibitor
TW202521536A (zh) 2019-05-05 2025-06-01 美商基尼特奇公司 Cdk抑制劑
KR20220088699A (ko) 2019-09-27 2022-06-28 디스크 메디슨, 인크. 골수섬유증 및 관련 상태의 치료 방법
KR20230012539A (ko) 2020-05-13 2023-01-26 디스크 메디슨, 인크. 골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체
CN113880813B (zh) * 2020-07-01 2024-05-28 杭州百诚医药科技股份有限公司 一种2-氨基嘧啶类杂环化合物及应用
CN116113628A (zh) * 2020-08-31 2023-05-12 甘李药业股份有限公司 一种含cdk4/6抑制剂的药物组合物
EP4277902A4 (en) * 2021-01-07 2024-12-18 Ontario Institute for Cancer Research (OICR) ISOINDOLINONE-AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF NUAK KINASES, COMPOSITIONS AND USES THEREOF
CN115073425B (zh) * 2021-03-16 2023-11-14 中国科学院上海药物研究所 一类作为tbk1抑制剂的化合物、包含其的药物组合物及其用途
CN115160341B (zh) * 2022-07-18 2023-07-18 中国医学科学院医学实验动物研究所 苯并噁嗪类化合物及其药物用途

Family Cites Families (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4876252A (en) 1986-01-13 1989-10-24 American Cyanamid Company 4,5,6-substituted-N-(substituted-phenyl)-2-pyrimidinamines
US4788195A (en) 1986-01-13 1988-11-29 American Cyanamid Company 4,5,6-substituted-N-(substituted-phenyl)-2-pyrimidinamines
US5728536A (en) 1993-07-29 1998-03-17 St. Jude Children's Research Hospital Jak kinases and regulation of Cytokine signal transduction
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
CN1142817A (zh) 1993-10-12 1997-02-12 杜邦麦克制药有限公司 1n-烷基-n-芳基嘧啶胺及其衍生物
US6316635B1 (en) 1995-06-07 2001-11-13 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
US6696448B2 (en) 1996-06-05 2004-02-24 Sugen, Inc. 3-(piperazinylbenzylidenyl)-2-indolinone compounds and derivatives as protein tyrosine kinase inhibitors
GB9619284D0 (en) 1996-09-16 1996-10-30 Celltech Therapeutics Ltd Chemical compounds
GB9622363D0 (en) 1996-10-28 1997-01-08 Celltech Therapeutics Ltd Chemical compounds
US6486185B1 (en) 1997-05-07 2002-11-26 Sugen, Inc. 3-heteroarylidene-2-indolinone protein kinase inhibitors
US6316429B1 (en) 1997-05-07 2001-11-13 Sugen, Inc. Bicyclic protein kinase inhibitors
EP0994860A1 (en) 1997-07-03 2000-04-26 Du Pont Pharmaceuticals Company Aryl-and arylamino-substituted heterocycles as corticotropin releasing hormone antagonists
GB9718913D0 (en) 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
US6133305A (en) 1997-09-26 2000-10-17 Sugen, Inc. 3-(substituted)-2-indolinones compounds and use thereof as inhibitors of protein kinase activity
AU4851599A (en) 1998-06-30 2000-01-17 Parker Hughes Institute Method for inhibiting c-jun expression using jak-3 inhibitors
KR20010089171A (ko) 1998-08-21 2001-09-29 추후제출 퀴나졸린 유도체
US6841567B1 (en) 1999-02-12 2005-01-11 Cephalon, Inc. Cyclic substituted fused pyrrolocarbazoles and isoindolones
US6624171B1 (en) 1999-03-04 2003-09-23 Smithkline Beecham Corporation Substituted aza-oxindole derivatives
GB9904995D0 (en) 1999-03-04 1999-04-28 Glaxo Group Ltd Substituted aza-oxindole derivatives
US6080747A (en) 1999-03-05 2000-06-27 Hughes Institute JAK-3 inhibitors for treating allergic disorders
US7125875B2 (en) 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
CZ2002534A3 (cs) 1999-08-13 2002-07-17 Vertex Pharmaceuticals Incorporated Inhibitory protein-kináz, farmaceutické prostředky, které je obsahují, a jejich pouľití
GB9924862D0 (en) 1999-10-20 1999-12-22 Celltech Therapeutics Ltd Chemical compounds
AU4903201A (en) 1999-11-30 2001-07-03 Parker Hughes Institute Inhibitors of thrombin induced platelet aggregation
CZ303875B6 (cs) 1999-12-10 2013-06-05 Pfizer Products Inc. Pyrrolo[2,3-d]pyrimidinová sloucenina a farmaceutická kompozice s jejím obsahem
AR029423A1 (es) 1999-12-21 2003-06-25 Sugen Inc Compuesto derivado de pirrolo-[pirimidin o piridin]-6-ona, metodo de preparacion de dichos compuestos, composiciones farmaceuticas que los comprenden, un metodo para regular, modular o inhibir la actividad de la proteina quinasa y un metodo de tratar o prevenir una enfermedad de mamiferos
AU2968701A (en) 2000-01-24 2001-07-31 Genzyme Corporation Jak/stat pathway inhibitors and the uses thereof
CA2369076A1 (en) 2000-02-05 2001-08-09 Vertex Pharmaceuticals Incorporated Pyrazole compositions useful as inhibitors of erk
CZ20013540A3 (cs) 2000-02-05 2002-03-13 Vertex Pharmaceuticals Incorporated Deriváty pyrazolu jako inhibitory ERK a farmaceutický prostředek, který je obsahuje
US6608048B2 (en) 2000-03-28 2003-08-19 Wyeth Holdings Tricyclic protein kinase inhibitors
AR028261A1 (es) 2000-03-28 2003-04-30 Wyeth Corp Inhibidores triciclicos de la proteina quinasa
EA006153B1 (ru) 2000-06-26 2005-10-27 Пфайзер Продактс Инк. СОЕДИНЕНИЯ ПИРРОЛО[2,3-d]ПИРИМИДИНА В КАЧЕСТВЕ ИММУНОДЕПРЕССАНТОВ
GB0022438D0 (en) 2000-09-13 2000-11-01 Novartis Ag Organic Compounds
WO2002043735A1 (en) 2000-11-29 2002-06-06 Parker Hughes Institute Inhibitors of thrombin induced platelet aggregation
ES2307667T3 (es) 2000-12-05 2008-12-01 Vertex Pharmaceuticals Incorporated Inhibidires de quinasas terminales c-jun(jnk) y otras proteinas quinasas.
US20020115173A1 (en) 2000-12-11 2002-08-22 Children's Medical Center Corporation Short peptides from the 'A-region' of protein kinases which selectively modulate protein kinase activity
CA2432114A1 (en) 2000-12-20 2002-07-18 Sugen, Inc. 4-(hetero)aryl substituted indolinones
WO2002060492A1 (en) 2001-01-30 2002-08-08 Cytopia Pty Ltd Methods of inhibiting kinases
AUPR279101A0 (en) 2001-01-30 2001-02-22 Cytopia Pty Ltd Protein kinase signalling
MY130778A (en) 2001-02-09 2007-07-31 Vertex Pharma Heterocyclic inhibitiors of erk2 and uses thereof
ATE416175T1 (de) 2001-02-20 2008-12-15 Astrazeneca Ab 2-arylaminopyrimidine zur behandlung von mit gsk3 in zusammenhang stehenden erkrankungen
CA2441733A1 (en) 2001-03-29 2002-10-10 Vertex Pharmaceuticals Incorporated Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
JP2004535381A (ja) 2001-04-13 2004-11-25 バーテックス ファーマシューティカルズ インコーポレイテッド c−JunN末端キナーゼ(JNK)および他のプロテインキナーゼのインヒビター
US7301023B2 (en) 2001-05-31 2007-11-27 Pfizer Inc. Chiral salt resolution
JP4523271B2 (ja) 2001-06-01 2010-08-11 バーテックス ファーマシューティカルズ インコーポレイテッド プロテインキナーゼのインヒビターとして有用なチアゾール化合物
EP1399440B1 (en) 2001-06-15 2009-06-03 Vertex Pharmaceuticals Incorporated 5-(2-aminopyrimidin-4-yl)benzisoxazoles as protein kinase inhibitors
DE60214198T2 (de) 2001-07-03 2007-08-09 Vertex Pharmaceuticals Inc., Cambridge Isoxazolyl-pyrimidines als inhibitoren von src- und lck-protein-kinasen
WO2003011837A1 (en) 2001-08-01 2003-02-13 Merck & Co., Inc. Tyrosine kinase inhibitors
US6433018B1 (en) 2001-08-31 2002-08-13 The Research Foundation Of State University Of New York Method for reducing hypertrophy and ischemia
AU2002334355A1 (en) 2001-09-06 2003-03-18 Prochon Biotech Ltd. Protein tyrosine kinase inhibitors
WO2003022815A1 (en) 2001-09-10 2003-03-20 Sugen, Inc. 3-(4,5,6,7-tetrahydroindol-2-ylmethylidiene)-2-indolinone derivatives as kinase inhibitors
WO2003030909A1 (en) 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
GT200200234A (es) 2001-12-06 2003-06-27 Compuestos cristalinos novedosos
ES2262899T3 (es) 2001-12-17 2006-12-01 Smithkline Beecham Corporation Derivados de pirazolopiridazina.
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
US6998391B2 (en) 2002-02-07 2006-02-14 Supergen.Inc. Method for treating diseases associated with abnormal kinase activity
CA2485429A1 (en) 2002-05-06 2004-07-15 Vertex Pharmaceuticals Incorporated Thiadiazoles or oxadiazoles and their use as inhibitors of jak protein kinase
KR20050013562A (ko) 2002-05-30 2005-02-04 버텍스 파마슈티칼스 인코포레이티드 Jak 및 cdk2 프로테인 키나아제의 억제제
CA2491895C (en) 2002-07-09 2011-01-18 Vertex Pharmaceuticals Incorporated Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
GB0215844D0 (en) * 2002-07-09 2002-08-14 Novartis Ag Organic compounds
CN103169708B (zh) 2002-07-29 2018-02-02 里格尔药品股份有限公司 用2,4‑嘧啶二胺化合物治疗或者预防自体免疫性疾病的方法
RU2005106871A (ru) 2002-08-14 2005-10-10 Вертекс Фармасьютикалз Инкорпорейтед (Us) Ингибиторы протеинкиназ и их применение
EP2172460A1 (en) 2002-11-01 2010-04-07 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of JAK and other protein kinases
US7259161B2 (en) 2002-11-04 2007-08-21 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of JAK and other protein kinases
AU2003286895A1 (en) * 2002-11-05 2004-06-07 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of jak and other protein kinases
GB0226583D0 (en) 2002-11-14 2002-12-18 Cyclacel Ltd Compounds
AR042052A1 (es) 2002-11-15 2005-06-08 Vertex Pharma Diaminotriazoles utiles como inhibidores de proteinquinasas
EP1572649A2 (en) 2002-11-21 2005-09-14 Pfizer Products Inc. 3-amino-piperidine derivatives and processes for their preparation
CA2507392A1 (en) 2002-11-26 2004-06-10 Pfizer Products Inc. Method of treatment of transplant rejection
US7226919B2 (en) 2002-12-18 2007-06-05 Vertex Pharmaceuticals Inc. Compositions useful as inhibitors of protein kinases
WO2004087698A2 (en) 2003-03-25 2004-10-14 Vertex Pharmaceuticals Incorporated Thiazoles useful as inhibitors of protein kinases
AU2004225977B2 (en) 2003-03-25 2011-03-24 Vertex Pharmaceuticals Incorporated Thiazoles useful as inhibitors of protein kinases
JP2006522124A (ja) 2003-04-03 2006-09-28 バーテックス ファーマシューティカルズ インコーポレイテッド プロテインキナーゼのインヒビターとして有用な組成物
DK1620437T3 (da) 2003-04-29 2009-08-24 Pfizer Ltd 5,7-diaminopyrazolo-4,3-d-pyrimidiner, der er anvendelige til behandling af hypertension
AU2003232650A1 (en) 2003-05-06 2004-11-26 Il Yang Pharm Co., Ltd. N-phenyl-2-pyrimidine-amine derivatives and process for the preparation thereof
AU2004259734A1 (en) 2003-07-24 2005-02-03 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2005012262A1 (en) 2003-07-30 2005-02-10 Cyclacel Limited 2-aminophenyl-4-phenylpyrimidines as kinase inhibitors
US7122542B2 (en) 2003-07-30 2006-10-17 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
BRPI0412351A (pt) 2003-07-30 2006-09-05 Cyclacel Ltd derivados e piridilamino-pirimidina como inibidores de proteìna quinase
KR20060037442A (ko) 2003-08-14 2006-05-03 화이자 인코포레이티드 Hiv 감염 치료용 피페라진 유도체
TWI339206B (en) 2003-09-04 2011-03-21 Vertex Pharma Compositions useful as inhibitors of protein kinases
AP2174A (en) 2003-10-03 2010-11-20 Pfizer Imidazopyridine substituted tropane derivatives with CCR5 receptor antagonist activity for the treatment of HIV and inflamation.
US7169781B2 (en) 2003-10-17 2007-01-30 Hoffmann-La Roche Inc. Imidazole derivatives and their use as pharmaceutical agents
TW200528101A (en) 2004-02-03 2005-09-01 Astrazeneca Ab Chemical compounds
GB0402653D0 (en) 2004-02-06 2004-03-10 Cyclacel Ltd Compounds
EP1751136B1 (en) 2004-05-07 2014-07-02 Amgen Inc. Nitrogenated heterocyclic derivatives as protein kinase modulators and use for the treatment of angiogenesis and cancer
GB0411791D0 (en) 2004-05-26 2004-06-30 Cyclacel Ltd Compounds
CA2578122A1 (en) 2004-08-27 2006-03-02 Gpc Biotech Ag Pyrimidine derivatives
ATE540035T1 (de) 2004-11-24 2012-01-15 Rigel Pharmaceuticals Inc Spiro-2,4-pyrimidindiamin-verbindungen und ihre verwendungen
DE602005014382D1 (de) 2004-12-21 2009-06-18 Smithkline Beecham Corp 2-pyrimidinyl-pyrazolopyridin-erbb-kinaseinhibitoren
US7449458B2 (en) 2005-01-19 2008-11-11 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
GB0504753D0 (en) 2005-03-08 2005-04-13 Astrazeneca Ab Chemical compounds
WO2007018941A2 (en) 2005-07-26 2007-02-15 Smithkline Beecham Corporation Pyrimidyl-thiophene derivatives
WO2007024843A2 (en) 2005-08-26 2007-03-01 Smithkline Beecham Corporation Pyrimidinyl-pyrazole inhibitors of aurora kinases
WO2007030680A2 (en) 2005-09-07 2007-03-15 Rigel Pharmaceuticals, Inc. Triazole derivatives useful as axl inhibitors
DE102005048072A1 (de) 2005-09-24 2007-04-05 Bayer Cropscience Ag Thiazole als Fungizide
GB0520955D0 (en) * 2005-10-14 2005-11-23 Cyclacel Ltd Compound
US7803806B2 (en) * 2005-11-03 2010-09-28 Sgx Pharmaceuticals, Inc. Pyrimidinyl-thiophene kinase modulators
JP5103403B2 (ja) 2005-12-05 2012-12-19 スミスクライン ビーチャム コーポレーション 2−ピリミジニルピラゾロピリジンErbBキナーゼ阻害剤
EP1979329A2 (en) * 2006-01-30 2008-10-15 Exelixis, Inc. 4-aryl-2-amino-pyrimidines or 4-aryl-2-aminoalkyl-pyrimidines as jak-2 modulators and methods of use
WO2007132221A1 (en) 2006-05-12 2007-11-22 Cyclacel Limited Combined anticancer pyrimidine-thiazole aurora kinase inhibitors
JP2009542604A (ja) * 2006-07-06 2009-12-03 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 4−ヘテロシクロアルキルピリミジン、それらの調製方法及び医薬としての使用
WO2008045978A1 (en) 2006-10-10 2008-04-17 Rigel Pharmaceuticals, Inc. Pinane-substituted pyrimidinediamine derivatives useful as axl inhibitors
WO2008080134A2 (en) 2006-12-22 2008-07-03 Rigel Pharmaceuticals, Inc. 4-amin0-2- (hetero) arylamino-5- (hetero) arylthiazoles useful as axl inhibitors
CN101622252B (zh) 2006-12-29 2015-04-22 里格尔制药公司 用作axl抑制剂的取代三唑
ES2607065T3 (es) 2006-12-29 2017-03-29 Rigel Pharmaceuticals, Inc. Triazoles N3-heteroaril sustituidos y triazoles N5-heteroaril sustituidos útiles como inhibidores de axl
ME01832B (me) 2006-12-29 2014-12-20 Rigel Pharmaceuticals Inc Policiklični heteroaril supstituisani triazoli koji su korisni kao axl inhibitori
CA2710043C (en) 2006-12-29 2016-02-09 Rigel Pharmaceuticals, Inc. Bicyclic aryl and bicyclic heteroaryl substituted triazoles useful as axl inhibitors
PL2114955T3 (pl) 2006-12-29 2013-06-28 Rigel Pharmaceuticals Inc Triazole podstawione mostkowanym bicyklicznym arylem oraz mostkowanym bicyklicznym heteroarylem użyteczne jako inhibitory Axl
HUE029188T2 (en) * 2007-03-12 2017-03-28 Ym Biosciences Australia Pty Phenylamino-pyrimidine compounds and their use
US8093239B2 (en) 2007-06-01 2012-01-10 Glaxosmithkline Llc Imidazopyridine kinase inhibitors
JP5635909B2 (ja) 2007-10-26 2014-12-03 ライジェル ファーマシューティカルズ, インコーポレイテッド Axl阻害剤として有用な多環アリール置換トリアゾール及び多環ヘテロアリール置換トリアゾール
HRP20170317T1 (hr) 2008-02-15 2017-04-21 Rigel Pharmaceuticals, Inc. Spojevi pirimidin-2-amina i njihova uporaba kao inhibitora jak kinaza
CA2730231C (en) 2008-07-09 2016-10-18 Rigel Pharmaceuticals, Inc. Polycyclic heteroaryl substituted triazoles useful as axl inhibitors
CA2730251C (en) 2008-07-09 2016-08-09 Rigel Pharmaceuticals, Inc. Bridged bicyclic heteroaryl substituted triazoles useful as axl inhibitors
BRPI1007046B1 (pt) 2009-01-16 2019-07-16 Rigel Pharmaceuticals, Inc. Inibidores axl para uso em terapia de combinação para evitar, tratar ou controlar o câncer metastático.

Also Published As

Publication number Publication date
CA2715658C (en) 2016-07-19
AU2009214440A1 (en) 2009-08-20
ES2617622T3 (es) 2017-06-19
IL207609A0 (en) 2010-12-30
JP5711537B2 (ja) 2015-05-07
KR101700454B1 (ko) 2017-01-26
US8309566B2 (en) 2012-11-13
CN102007124B (zh) 2014-06-18
WO2009103032A1 (en) 2009-08-20
MX2010008926A (es) 2011-02-23
JP2015061846A (ja) 2015-04-02
PT2265607T (pt) 2017-03-08
IL207609A (en) 2015-08-31
DK2265607T3 (en) 2017-03-13
US20140213585A1 (en) 2014-07-31
CA2715658A1 (en) 2009-08-20
HUE030912T2 (en) 2017-06-28
NZ587589A (en) 2012-10-26
CN102007124A (zh) 2011-04-06
US8735418B2 (en) 2014-05-27
JP2011512361A (ja) 2011-04-21
US20090258864A1 (en) 2009-10-15
LT2265607T (lt) 2017-03-27
CY1118969T1 (el) 2018-01-10
KR20100124292A (ko) 2010-11-26
US9624229B2 (en) 2017-04-18
AU2009214440B2 (en) 2014-09-25
EP2265607B1 (en) 2016-12-14
HRP20170317T1 (hr) 2017-04-21
PL2265607T3 (pl) 2017-07-31
EP2265607A1 (en) 2010-12-29
US20130018041A1 (en) 2013-01-17

Similar Documents

Publication Publication Date Title
IL207609A0 (en) Pyrimidine-2-amine compounds and their use as inhibitors of jak kinases
ZA201100211B (en) Kinase inhibitors and methods of use
EP2252293A4 (en) KINASEHEMMER AND USE PROCESS
IL208719A0 (en) Inhibitors of protein kinases
ZA201101586B (en) Aminotriazolopyridines and their use as kinase inhibitors
PH12012500712A1 (en) Inhibitors of bruton`s tyrosine kinase
EP2445885A4 (en) SUBSTITUTED HETEROCYCLIC COMPOUNDS AS CHINESE INHIBITORS AND METHOD FOR THEIR USE
IL205043A0 (en) Inhibitors of c - fms kinase
ZA201208544B (en) 5,7-substitute-imidazo [1,2-c] pyrimidines as inhibitors of jak kinases
PT2320911E (pt) Composições de vasoconstrição e métodos de utilização
IL213547A0 (en) Compounds and methods of use
EP2340244A4 (en) COMPOUNDS AND APPLICATION PROCEDURES
IL210462A0 (en) Pyrimidine compounds, compositions and methods of use
IL212586A0 (en) Benzoxazole kinase inhibitors and methods of use
IL217222A0 (en) Phosphorus containing quinazoline compounds and methods of use
ZA201000183B (en) Quinazolinone compounds and methods of use thereof
EP2323659A4 (en) COMPOUNDS USEFUL AS INHIBITORS OF PROTEIN KINASES
ZA201008026B (en) Inhibitors of ikk-b serine-threonine protein kinase
PL2237782T3 (pl) Zastosowanie tetrahydropirymidyn
ZA201300012B (en) Synthesis and use of kinase inhibitors
GB0907120D0 (en) Inhibitors of IKK-ß serine-threonine protein kinase
GB0805693D0 (en) Combinations of P13-delta and P13-gamma kinase inhibitor compounds
GB0719877D0 (en) Inhibitors of protein kinases